ESH Video

23rd Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy

23rd Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
October 08 - October 10, 2021 - Mandelieu-La Napoule, France
Chairs : Jorge Cortes, Tim P. Hughes, Daniela S. Krause

Information

23rd John Goldman Conference

Chronic Myeloid Leukemia: Biology and Therapy

Mandelieu-La Napoule, France
October 8-10, 2021
#ESHCML2021

Chairs: J. Cortes, T. P. Hughes, D. S. Krause

Organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, F.X. Mahon, D. Perrotti, J. Radich, D. Réa

Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann, P. Laneuville, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten

 

The Program will include:

  • John Goldman Prize
  • Janet Rowley Prize
  • iCMLf Prize
  • Keynote lectures
  • Special lectures
  • Oral communications selected from submitted abstracts
  • Brief oral communications selected from submitted abstracts
  • Workshops for non-clinical scientists
  • Meet-the-Expert Sessions
  • Clinical and biology manned poster walks
  • 2021 Saturday Clinical symposium 

 

Educational Objectives: 

Upon completion of this CME activity, participants should be able to:

1. Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.

2. Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.

3. Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.

4. Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.

5. Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.

6. Assess the role of allogeneic stem cell transplantation in the management of CML.

7. Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.

8. Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.

9. Discuss patient reported outcomes and their role in the management of patients with CML.

 

Programme

Abstract submission

Abstract submission

Deadline: May 8th, 2021

 

CLICK HERE TO SUBMIT YOUR ABSTRACT

 

Abstracts guidelines:
– Your abstract has to be structured (eg Objectives, Methods, Results, Conclusions)
– Maximum number of words: 400
– Your abstract will be submitted to the peer review procedure.

The following file types may be uploaded: HTML document (*.htm), HTML document (*.html), JPEG image (*.jpg), GIF image (*.gif), or PNG image (*.png).

Symposia

Accommodation

Venue

Corporate partners

Scholarships

Workshop

Educational Grants

Registration